Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

By Andreas Hochhaus, H. Kantarjian, M. Baccarani, J. Lipton, J. Apperley, Brian J. Druker, T. Facon, S. Goldberg, F. Cervantes, D. Niederwieser and 7 more. Blood, 2007

616 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/24f3c3eee8b540af9716dba5627371f6b449ef47

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Zhesheng Chen
2. C. Ashby
3. J. Cortes
4. Andreas Hochhaus
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

In Hematology

1. J. Cortes
2. C. Ashby
3. Zhesheng Chen
4. J. Apperley
5. Andreas Hochhaus
6. J. Goldman
7. H. Kantarjian
8. M. Baccarani

In Rheumatology

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

Citations in the corpus

• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007, background): “Median duration of disease, mo (range) 57 (5-275)”
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009, result): “8 months.(22,23) In patients with imatinib-resistant disease in CP, the MCgR and the CCgR rates were 51% and 40%, respectively, in one study(22,23) and were 50% and 36%, respectively, in another study.”
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “[70] Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al.”
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007, positive): “As expected, the three patients with T315I did not show any response to dasatini”